Sign up to save your podcasts
Or
Share Ashwini Ghogare - AI, Automation and Drug Discovery (FODD #14)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ashwini Ghogare - AI, Automation and Drug Discovery (FODD #14)
In this episode, we speak with Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery at MilliporeSigma, the Global Science and Technology Group at Merck.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
X: https://twitter.com/AntiverseHQ
View all episodes
In this episode, we speak with Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery at MilliporeSigma, the Global Science and Technology Group at Merck.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
X: https://twitter.com/AntiverseHQ